# Anti-inflammatory effects of Glehnia littoralis ethyl acetate extract and its active compound phellopterin via inhibition of N-acylethanolamine acid amidase. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/glehnia-littoralis-anti-inflammatory-effects-namaa-inhibition/ > **Published:** 2026-04-11T03:06:55-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:56:29-04:00 > **Clinical Summary:** Explore glehnia littoralis anti-inflammatory properties through N-acylethanolamine acid amidase inhibition and its potential in traditional botanical medicine. --- CED Clinical Relevance  #50Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic InflammationTraditional MedicineEndocannabinoidPreclinicalNaaa Journal Journal of ethnopharmacology Study Type Clinical Study Population Human participants Why This Matters This study identifies a novel mechanism by which traditional anti-inflammatory botanicals may work—through inhibition of N-acylethanolamine acid amidase (NAAA), an enzyme that degrades endocannabinoid-like compounds. Understanding these pathways could inform integration of traditional medicines with cannabinoid-based therapies. Clinical Summary Researchers used bioactivity-guided fractionation to identify active anti-inflammatory compounds from Glehnia littoralis root, a traditional East Asian medicine. The ethyl acetate fraction showed the strongest activity in both NAAA enzyme inhibition assays and LPS-induced inflammation models using RAW264.7 cells. Two specific compounds, phellopterin and cnidilin, were identified as key NAAA inhibitors responsible for the [anti-inflammatory effects](https://cedclinic.com/cbd-antioxidative-anti-inflammatory-properties-benefits/). The study provides molecular mechanism data for a traditionally used botanical medicine, though clinical translation remains to be demonstrated. Dr. Caplan’s Take “I find the NAAA inhibition mechanism particularly intriguing given its role in endocannabinoid metabolism. However, this remains preclinical work—we need human data before drawing clinical conclusions about efficacy or safety.” Clinical Perspective 🧠 Clinicians should view this as promising mechanistic research that may eventually inform botanical medicine selection, but should not alter current practice based on these laboratory findings alone. Patients interested in traditional anti-inflammatory approaches should continue working with qualified practitioners while awaiting clinical validation of these mechanisms. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Anti-inflammatory%20effects%20of%20Glehnia%20littoralis%20ethyl%20acetate%20extract%20and%20its%20ac...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41887380/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41887380/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Anti-inflammatory%20effects%20of%20Glehnia%20littoralis%20ethyl%20acetate%20extract%20and%20its%20ac...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41887380/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41887380/](https://pubmed.ncbi.nlm.nih.gov/41887380/) Table of Contents - [FAQ](#FAQ)[What is Glehnia littoralis and how does it relate to cannabis therapeutics?](#What_is_Glehnia_littoralis_and_how_does_it_relate_to_cannabis_therapeutics) - [How does NAAA inhibition contribute to anti-inflammatory effects?](#How_does_NAAA_inhibition_contribute_to_anti-inflammatory_effects) - [What are the key active compounds identified in this research?](#What_are_the_key_active_compounds_identified_in_this_research) - [What is the clinical relevance of this preclinical research?](#What_is_the_clinical_relevance_of_this_preclinical_research) - [Should patients consider Glehnia littoralis for inflammatory conditions?](#Should_patients_consider_Glehnia_littoralis_for_inflammatory_conditions) - [Related](#Related) ## FAQ #### What is Glehnia littoralis and how does it relate to cannabis therapeutics? Glehnia littoralis is a traditional East Asian medicinal plant whose root is used to treat inflammatory lung conditions. This study found that its ethyl acetate extract inhibits N-acylethanolamine acid amidase (NAAA), an enzyme that degrades endocannabinoid-like molecules, potentially enhancing the body’s natural anti-inflammatory pathways. #### How does NAAA inhibition contribute to anti-inflammatory effects? NAAA breaks down N-acylethanolamines, which are endogenous lipid mediators similar to endocannabinoids that help regulate inflammation. By inhibiting NAAA, Glehnia littoralis extract allows these anti-inflammatory molecules to remain active longer, potentially reducing chronic inflammatory responses through the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/). #### What are the key active compounds identified in this research? The study identified phellopterin and cnidilin as the primary bioactive constituents responsible for NAAA inhibition in the ethyl acetate fraction of Glehnia littoralis. These compounds showed significant anti-inflammatory activity in laboratory cell models of inflammation. #### What is the clinical relevance of this preclinical research? This research provides early-stage evidence for understanding how traditional anti-inflammatory herbs may work through endocannabinoid-related pathways. However, as preclinical research, it requires further clinical studies before any therapeutic recommendations can be made for human inflammatory conditions. #### Should patients consider Glehnia littoralis for inflammatory conditions? While this study shows promising anti-inflammatory mechanisms, it represents early laboratory research that has not been tested in human [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/). Patients should consult healthcare providers before using traditional herbal preparations, especially when managing chronic inflammatory conditions that may require established medical treatments. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoid use is linked to both pro- and anti-inflammatory effects, massive review finds](https://cedclinic.com/cannabinoid-effects-on-inflammation-complex-bidirectional-review/) A comprehensive review exploring how cannabinoids can have both pro-inflammatory and [anti-inflammatory effects](https://cedclinic.com/cbd-antioxidative-anti-inflammatory-properties-benefits/), relevant to understanding botanical anti-inflammatory mechanisms. [Read the review](https://cedclinic.com/cannabinoid-effects-on-inflammation-complex-bidirectional-review/) [Cannabis compounds show promise in fighting fatty liver disease, scientists say – AZERTAC](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) Research highlighting the therapeutic potential of [cannabis compounds](https://cedclinic.com/cannabis-terpene-synergy-entourage-effect/) in inflammatory-related liver disease, providing context for botanical anti-inflammatory studies. [Explore the research](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) [Opioids and Cannabis: An Uncertain Combination?](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) An analysis of the complex interactions between opioids and cannabis, relevant for understanding multi-modal approaches to inflammation and [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/). [Learn more](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).